PMID- 15921627
OWN - NLM
STAT- MEDLINE
DCOM- 20090209
LR  - 20220330
IS  - 0253-2727 (Print)
IS  - 0253-2727 (Linking)
VI  - 26
IP  - 2
DP  - 2005 Feb
TI  - [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during 
      its treatment of childhood acute lymphoblastic leukemia].
PG  - 100-2
AB  - OBJECTIVE: To investigate the changes in the activity of Escherichia coli 
      asparaginase (L-asp) and the concentration of asparagines (ASN) in the plasma of 
      the acute lymphoblastic leukemia (ALL) children receiving L-asp containing 
      chemotherapeutic protocol to explore more reasonable usage of L-asp in the 
      treatment of childhood ALL. METHODS: L-asp containing hemotherapy regimen of VDLP 
      was used, in which L-asp (10,000 U/m(2)) was administered intravenously every 
      other day for 10 doses in 15 children with ALL. A total of 340 peripheral blood 
      samples were collected at scheduled time points during the therapy and plasma 
      L-asp activity (by spectrophotometric assay) and asparagines concentration (by 
      RP-HPLC) were measured. RESULTS: During the administration of L-asp, the plasma 
      L-asp activity was increasing gradually peaked after eight doses and then 
      decreased gradually, while the plasma concentration of asparagines maintained in 
      complete or nearly complete depletion status. After the therapy courses finished, 
      a plasma L-asp activity above 100 U/L with asparagines almost complete depletion 
      status was lasting for about seven days. CONCLUSION: The current L-asp containing 
      chemotherapeutic protocols in which L-asp was administered in a dose of 10 
      000/m(2) intravenously every other day, are efficient enough for the depletion of 
      plasma ASN.
FAU - Chen, Fu-xiong
AU  - Chen FX
AD  - Department of Pediatrics, the First Affiliated Hospital of Guangzhou Medical 
      College, Guangzhou 510120, China.
FAU - Cui, Yan-qin
AU  - Cui YQ
FAU - Wu, Zi-liang
AU  - Wu ZL
FAU - Ye, Tie-zhen
AU  - Ye TZ
FAU - Lai, Yong-hong
AU  - Lai YH
FAU - Zou, Ya-wei
AU  - Zou YW
FAU - Lu, Cheng-yu
AU  - Lu CY
FAU - Guan, Jing-ming
AU  - Guan JM
FAU - Wei, Feng-gui
AU  - Wei FG
FAU - Zhang, Hui
AU  - Zhang H
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 7006-34-0 (Asparagine)
RN  - EC 3.5.1.1 (Asparaginase)
SB  - IM
MH  - Adolescent
MH  - Antineoplastic Combined Chemotherapy 
      Protocols/blood/*pharmacokinetics/therapeutic use
MH  - Asparaginase/administration & dosage/blood/*pharmacokinetics
MH  - Asparagine/*blood
MH  - Child
MH  - Child, Preschool
MH  - Drug Administration Schedule
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood/*drug therapy
MH  - Treatment Outcome
EDAT- 2005/06/01 09:00
MHDA- 2009/02/10 09:00
CRDT- 2005/06/01 09:00
PHST- 2005/06/01 09:00 [pubmed]
PHST- 2009/02/10 09:00 [medline]
PHST- 2005/06/01 09:00 [entrez]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2005 Feb;26(2):100-2.